Cenobamate

證據等級: L5

預測適應症: 10 個

Cenobamate: From Focal Seizures to Status Epilepticus

One-Sentence Summary

Cenobamate (Xcopri®/Ontozry®) is a third-generation antiseizure medication with a novel dual mechanism, approved in the US (2019) and EU (2021) for adjunctive treatment of focal seizures in adults, but not yet marketed in Taiwan. The TxGNN model predicts it may be effective for Status Epilepticus (ranked #2, score 97.48%), with mechanistic plausibility grounded in its unique ability to modulate GABA-A receptors at a non-benzodiazepine site — directly addressing the receptor internalization that renders standard treatment ineffective in refractory SE. This direction is currently supported by 1 early-phase clinical trial (CENOBITE, NCT06352723) and 12 publications including case series documenting off-label use in super-refractory SE.

⚠️ Prediction ranking note: The highest-ranked TxGNN prediction (#1, score 97.83%) is Guanidinoacetate Methyltransferase Deficiency — a metabolic disorder where cenobamate may symptomatically address secondary epilepsy but has no effect on the underlying enzymatic defect, and carries a Hold recommendation with zero supporting clinical evidence. This report focuses on Status Epilepticus (#2), which presents the strongest clinical rationale and actionable evidence among all predictions.

Quick Overview

Item	Content
Original Indication	Focal seizures in adults (adjunctive; FDA-approved 2019, EMA-approved 2021; not registered in Taiwan)
Predicted New Indication	Status Epilepticus
TxGNN Prediction Score	97.48%
Evidence Level	L3
Taiwan Market Status	✗ Not marketed
Number of Authorizations (Taiwan)	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Cenobamate operates through a dual mechanism that is pharmacologically distinct from all other approved antiseizure medications. It preferentially inhibits the persistent sodium current (INaP) of voltage-gated sodium channels — the component responsible for sustained repetitive neuronal firing — while simultaneously acting as a positive allosteric modulator (PAM) of GABA-A receptors at a non-benzodiazepine binding site, enhancing inhibitory neurotransmission through a pathway that is independent of standard benzodiazepine targets. This combination is not incidental; it directly addresses two independent drivers of pathological neuronal excitability.

Status epilepticus (SE) is fundamentally defined by the failure of seizure self-termination, and the transition to benzodiazepine-resistant SE is driven at the molecular level by rapid endocytosis of γ₂-subunit-containing synaptic GABA-A receptors — precisely the receptor population that benzodiazepines require. Because cenobamate’s GABA-A PAM activity acts at a distinct binding site (likely δ-subunit, expressed in extrasynaptic receptors that are not subject to the same trafficking), it is theoretically positioned to retain efficacy even when the benzodiazepine pathway has collapsed. INaP blockade provides an orthogonal mechanism against the sustained depolarization that maintains seizure activity. Together, these two mechanisms map onto both core molecular events of established SE — a pharmacological convergence that is rare among available agents.

This rationale has attracted clinical attention. The CENOBITE study (NCT06352723), initiated by the Critical Care EEG Monitoring Consortium, targets cenobamate specifically in ICU patients with acute seizure clusters and status epilepticus. Published case series (2023) document safe administration in super-refractory SE (SRSE) with controlled titration, and a 2025 safety correspondence provides early real-world clinical observations. The fact that academic critical care epileptologists have independently converged on this research question lends external validity to the TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06352723	Early Phase 1	Not Yet Recruiting	10	CENOBITE Study: Multi-center ICU trial through the Critical Care EEG Monitoring Consortium (CCEMRC). Evaluates cenobamate for acute frequent seizures and status epilepticus under continuous EEG monitoring. Includes super-refractory SE (SRSE) subgroup. Safety and feasibility primary focus. Expected completion: June 2025.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37064924	2023	Case Series	The Neurohospitalist	Two SRSE cases treated safely with cenobamate as add-on therapy; slow up-titration protocol used to mitigate hypersensitivity risk; proof-of-concept for ICU neurological use
39060539	2025	Safety Commentary	Neurological Sciences	Early safety observations from Italian neurological centers on cenobamate use in SE; practical guidance for critically ill patients
36929735	2023	Narrative Review	Epilepsia Open	Comprehensive review of SE pharmacology — presynaptic, postsynaptic, and extrasynaptic mechanisms; frames mechanism-based ASM selection and contextualizes cenobamate’s mechanistic positioning
37458794	2023	Review	Journal of Neurology	Advances in epilepsy treatment; cenobamate highlighted as a third-generation ASM with broad-spectrum anticonvulsant activity
40292823	2025	Retrospective Case Series	Epilepsia	⚠️ Safety signal: Lack of effectiveness and seizure worsening in 6 pediatric Dravet syndrome (SCN1A loss-of-function) patients — highlights the need for genetic subgroup exclusion criteria in SE trials
39388362	2024	Case Series	Epilepsia Open	Cenobamate add-on in Rasmussen’s encephalitis (highly pharmacoresistant progressive epilepsy); informative model for pharmacoresistant SE populations
40383002	2025	Observational Study	Epilepsy & Behavior	Single tertiary-center real-world experience; seizure-freedom rates at one year of cenobamate therapy
41007820	2025	Review	Biomedicines	Potential for disease-modifying therapy in epilepsy; cenobamate discussed in context of reducing seizure burden and neuronal injury
40763422	2025	Retrospective Cohort	Seizure	Italian multicenter study evaluating novel treatments in adults with severe epileptic phenotypes due to SSADHD
39267763	2024	Case Report	Frontiers in Immunology	Drug-resistant epilepsy in seronegative limbic encephalitis; cenobamate included in management of refractory seizures in acute encephalitis — a clinically adjacent scenario to SE

Taiwan Market Information

Cenobamate is not currently approved or marketed in Taiwan. There are no TFDA-authorized products and no health insurance reimbursement listing.

For clinical reference, cenobamate is available globally under the following authorizations:

Product Name	Region	Regulatory Body	Approved Indication	Approval Date
Xcopri®	United States	FDA	Adjunctive treatment of focal seizures in adults	November 2019
Ontozry®	European Union	EMA	Adjunctive treatment of focal seizures in adults	March 2021

Safety Considerations

Please refer to the SmPC for safety information.

⚠️ Key risk flagged from literature: Three cases of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) occurred during cenobamate clinical development, requiring implementation of a mandatory slow-titration protocol (start: 12.5 mg/day; target dose: 200 mg/day reached over months). In the acute SE/ICU context, where clinical urgency may pressure clinicians toward faster escalation, this represents a critical risk-benefit tension that any SE-specific protocol must explicitly address. Clinicians should review the DRESS mitigation strategy published in the Phase 3 open-label safety study (PMID 32396252) before any off-label SE use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Cenobamate’s dual mechanism — GABA-A PAM at a non-benzodiazepine site and persistent sodium channel blockade — maps directly onto the two molecular drivers of benzodiazepine-resistant status epilepticus, providing one of the strongest mechanistic arguments for any currently investigated SE candidate. The independent initiation of a dedicated clinical trial (CENOBITE, NCT06352723) by a leading academic critical care EEG consortium, combined with published case series confirming safe use in SRSE, justifies cautious forward movement.

To proceed, the following is needed:

CENOBITE trial results (NCT06352723, target completion June 2025): the most critical near-term data point — primary safety and feasibility outcomes in ICU SE patients
TFDA SmPC / safety data resolution (DG001): obtain and parse the cenobamate package insert to address Taiwan-specific warnings, contraindications, and DRESS management — currently a blocking gap for formal S1 safety evaluation
MOA documentation (DG002): confirm the specific GABA-A receptor subunit selectivity (δ vs. γ) and INaP inhibition profile for mechanism-focused regulatory and scientific communication
SE-specific dosing protocol: define a clinically feasible titration schedule that balances DRESS risk against the therapeutic urgency of refractory SE
Patient exclusion criteria: pre-specify genetic epilepsy exclusions (especially SCN1A-related disorders) based on the Dravet safety signal (PMID 40292823) before any Taiwan pilot use
TFDA regulatory pathway assessment: evaluate whether the existing US/EU approval for focal seizures can support an expedited NDA filing, and determine whether SE indication requires a separate clinical dossier
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.